Next Article in Journal
Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET
Next Article in Special Issue
Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study
Previous Article in Journal
Genetic and Phenotypic Analyses of a Papaver somniferum T-DNA Insertional Mutant with Altered Alkaloid Composition
Previous Article in Special Issue
Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees
Pharmaceuticals 2012, 5(2), 155-168; doi:10.3390/ph5020155

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

1,*  and 1,2
1 Krankenanstalt Rudolfstiftung, Second Medical Department, Juchgasse 25, Wien A-1030, Austria 2 Danube University Krems, Doktor-Karl-Dorrek-Straße 30, Krems A-3500, Austria
* Author to whom correspondence should be addressed.
Received: 26 December 2011 / Revised: 1 February 2012 / Accepted: 1 February 2012 / Published: 3 February 2012
(This article belongs to the Special Issue Anticoagulants)
View Full-Text   |   Download PDF [370 KB, uploaded 3 February 2012]


Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.
Keywords: atrial fibrillation; dabigatran; anticoagulation atrial fibrillation; dabigatran; anticoagulation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Stöllberger, C.; Finsterer, J. Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. Pharmaceuticals 2012, 5, 155-168.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert